Zacks Research Issues Pessimistic Outlook for TBPH Earnings

Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Zacks Research lowered their Q1 2025 earnings per share estimates for Theravance Biopharma in a research note issued on Wednesday, March 19th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings per share of ($0.43) for the quarter, down from their prior estimate of ($0.36). The consensus estimate for Theravance Biopharma's current full-year earnings is ($1.09) per share. Zacks Research also issued estimates for Theravance Biopharma's Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.29) EPS, Q1 2026 earnings at ($0.50) EPS, Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at $0.19 EPS, FY2026 earnings at ($1.13) EPS and FY2027 earnings at ($0.96) EPS.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.26). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The firm had revenue of $18.75 million during the quarter, compared to analyst estimates of $29.90 million.

Separately, HC Wainwright reiterated a "buy" rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research note on Tuesday, February 25th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $13.75.

Remove Ads

Theravance Biopharma Stock Up 0.1 %

Shares of TBPH traded up $0.01 during midday trading on Monday, reaching $9.31. 220,463 shares of the stock were exchanged, compared to its average volume of 288,020. The company has a market cap of $460.58 million, a price-to-earnings ratio of -9.22 and a beta of 0.15. Theravance Biopharma has a 12-month low of $7.44 and a 12-month high of $10.90. The firm has a 50 day simple moving average of $9.37 and a 200-day simple moving average of $9.08.

Insider Buying and Selling

In other news, SVP Rhonda Farnum sold 4,000 shares of the company's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 309,565 shares in the company, valued at approximately $2,786,085. This represents a 1.28 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 6.90% of the stock is owned by insiders.

Institutional Trading of Theravance Biopharma

A number of hedge funds have recently added to or reduced their stakes in TBPH. Invesco Ltd. grew its holdings in Theravance Biopharma by 3.5% during the 4th quarter. Invesco Ltd. now owns 46,050 shares of the biopharmaceutical company's stock worth $433,000 after acquiring an additional 1,576 shares during the period. Jane Street Group LLC increased its stake in Theravance Biopharma by 1.1% in the 3rd quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company's stock valued at $1,165,000 after buying an additional 1,640 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Theravance Biopharma by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company's stock valued at $2,766,000 after acquiring an additional 2,060 shares during the last quarter. Aquatic Capital Management LLC bought a new stake in shares of Theravance Biopharma during the 4th quarter worth $25,000. Finally, SG Americas Securities LLC boosted its stake in Theravance Biopharma by 21.1% in the fourth quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company's stock valued at $181,000 after acquiring an additional 3,349 shares during the last quarter. Institutional investors and hedge funds own 99.10% of the company's stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.